Background
Background Investigating the relationInvestigating the relationship between premorbid functioning and ship between premorbid functioning and treatment response in schizophrenia is treatment response in schizophrenia is relevantto understanding the illness and relevantto understanding the illness and predicting treatment outcomes. predicting treatment outcomes.
Aims Aims To examine the relationship
To examine the relationship between premorbid characteristics and between premorbid characteristics and treatment response of people with recenttreatment response of people with recentonset schizophrenia. onset schizophrenia.
Method
Method Data came from a large, Data came from a large, double-blind trial of recent-onset psychosis double-blind trial of recent-onset psychosis treated with a flexible dose of risperidone treated with a flexible dose of risperidone or haloperidol.Median treatment length or haloperidol.Median treatment length was 206 days.Premorbid functioning was was 206 days.Premorbid functioning was categorised using the Cannon-Spoor categorised using the Cannon-Spoor Premorbid Adjustment Scale. Premorbid Adjustment Scale.
Results
Results There were significant There were significant differences between the premorbid differences between the premorbid groups on change on the Positive and groups on change on the Positive and Negative Syndrome Scale,Clinical Global Negative Syndrome Scale,Clinical Global Impression severity and cognitive Impression severity and cognitive functioning and Extrapyramidal functioning and Extrapyramidal Symptoms Rating Scale.Patients in the Symptoms Rating Scale. Patients in the 'stable^good'premorbid group ( 'stable^good'premorbid group (n n¼251) 251) improved more than those in the'stableîmproved more than those in the'stablep oor' ( poor' (n n¼198) and 'declining ' ( 198) and 'declining' (n n¼81) 81) groups.The'stable^good'group received groups.The'stable^good'group received the lowest doses of antipsychotic and had the lowest doses of antipsychotic and had the least extrapyramidal symptoms. the least extrapyramidal symptoms. Patients in the'declining'group had the Patients in the'declining'group had the highest dosages and the most highest dosages and the most extrapyramidal symptoms. extrapyramidal symptoms.
Conclusions Conclusions In first-episode psychosis
In first-episode psychosis good premorbid functioning is associated good premorbid functioning is associated with better response to treatment and with better response to treatment and fewer extrapyramidal symptoms. fewer extrapyramidal symptoms.
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Good premorbid functioning among Good premorbid functioning among patients with schizophrenia and patients with schizophrenia and schizophrenia-like disorders is associated schizophrenia-like disorders is associated with better functioning at time of illness with better functioning at time of illness onset (Haas & Sweeney, 1992; Rabinowitz onset (Haas & Sweeney, 1992; Rabinowitz et al et al, 2002; Strous , 2002; Strous et al et al, 2004) and better , 2004) and better outcomes in both patients with a first epioutcomes in both patients with a first episode (Shtasel sode (Shtasel et al et al, 1992; Bromet , 1992; Bromet et al et al, , 1996; Silverstein 1996; Silverstein et al et al, 2002 Silverstein et al et al, , 2003 Strous , 2002 Strous , , 2003 Strous et al et al, 2004) and patients with chronic , 2004) and patients with chronic disorder (Gittelman-Klein & Klein, disorder (Gittelman-Klein & Klein, 1969; Cannon-Spoor 1969; Cannon-Spoor et al et al, 1982; Keefe , 1982; Keefe et al et al, 1989; Childers & Harding, 1990; , 1989; Childers & Harding, 1990; Findling Findling et al et al, 1996; Rabinowitz , 1996; Rabinowitz et al et al, , 2005) . Studies examined outcomes cross-2005). Studies examined outcomes crosssectionally but not longitudinally; hence, sectionally but not longitudinally; hence, it was not possible to be certain that the it was not possible to be certain that the observed association between good preobserved association between good premorbid functioning and favourable outmorbid functioning and favourable outcome was owing to a better response to come was owing to a better response to treatment in those with good premorbid treatment in those with good premorbid functioning. An alternative explanation functioning. An alternative explanation might be that better outcomes among might be that better outcomes among patients with good premorbid functioning patients with good premorbid functioning may reflect the fact that they had a less may reflect the fact that they had a less severe form of illness and therefore continsevere form of illness and therefore continued better functioning upon initiation of ued better functioning upon initiation of treatment. treatment.
The goal of our study was to compare The goal of our study was to compare treatment response in recent-onset psychotreatment response in recent-onset psychosis patients with good sis patients with good v v. poor premorbid . poor premorbid functioning in a large and lengthy clinical functioning in a large and lengthy clinical trial, in which the participants were trial, in which the participants were assessed prior to beginning antipsychotic assessed prior to beginning antipsychotic treatment and at regular intervals theretreatment and at regular intervals thereafter. The design of the trial allowed us to after. The design of the trial allowed us to examine the association between preexamine the association between premorbid functioning and treatment response morbid functioning and treatment response while controlling for baseline differences in while controlling for baseline differences in illness severity. illness severity.
METHOD METHOD
The data presented here consist of an analyThe data presented here consist of an analysis of a retrospectively collected premorbid sis of a retrospectively collected premorbid assessment, collected at time of entry into assessment, collected at time of entry into a double-blind, randomised controlled a double-blind, randomised controlled multicentre trial comparing a typical and multicentre trial comparing a typical and a novel antipsychotic drug in recent-onset a novel antipsychotic drug in recent-onset psychosis (Schooler psychosis (Schooler et al et al, 2005) , and the , 2005), and the baseline and end-point clinical, cognitive baseline and end-point clinical, cognitive and safety assessments of patients enrolled and safety assessments of patients enrolled in the trial. in the trial.
Participants Participants
The trial was conducted in 11 countries and The trial was conducted in 11 countries and enrolled psychotic patients aged 16-45 enrolled psychotic patients aged 16-45 years who had been given within the preyears who had been given within the previous 12 months a diagnosis (based on the vious 12 months a diagnosis (based on the Structured Clinical Interview for DSM-IV Structured Clinical Interview for DSM-IV Disorders; First Disorders; First et al et al, 1994) of schizo-, 1994) of schizophrenia, schizophreniform disorder or phrenia, schizophreniform disorder or schizoaffective disorder, and who had a schizoaffective disorder, and who had a maximum of two lifetime psychiatric hospimaximum of two lifetime psychiatric hospitalisations for psychosis. The cumulative talisations for psychosis. The cumulative exposure to antipsychotic drugs could not exposure to antipsychotic drugs could not have exceeded 12 weeks at the time of entry have exceeded 12 weeks at the time of entry to the study. Participants in both treatment to the study. Participants in both treatment groups started with a once-daily dose of groups started with a once-daily dose of 1 mg which could be increased to 2 mg on 1 mg which could be increased to 2 mg on day 4 and thereafter by 1 mg each week, day 4 and thereafter by 1 mg each week, up to a maximum daily dose of 4 mg. In exup to a maximum daily dose of 4 mg. In exceptional cases (i.e. for people showing inceptional cases (i.e. for people showing insufficient response in whom no more than sufficient response in whom no more than mild extrapyramidal symptoms were mild extrapyramidal symptoms were observed at a dosage of 4 mg per day), the observed at a dosage of 4 mg per day), the dosage could be increased further by 1 mg dosage could be increased further by 1 mg a week up to a maximum daily dose of a week up to a maximum daily dose of 8 mg. The mean modal total daily dosage 8 mg. The mean modal total daily dosage of risperidone was 3.3 mg and for haloperof risperidone was 3.3 mg and for haloperidol it was 2.9 mg. The most commonly taidol it was 2.9 mg. The most commonly taken daily dose for each of the drugs (mode ken daily dose for each of the drugs (mode dose) was 3 mg. The study was conducted dose) was 3 mg. The study was conducted according to good clinical practice (Food according to good clinical practice (Food and Drug Administration, 2005) and was and Drug Administration, 2005) and was approved by local institutional review approved by local institutional review boards. All participants gave informed boards. All participants gave informed written consent to take part in the study. written consent to take part in the study.
The flow of participants through the The flow of participants through the trial is shown in Fig. 1 . The final sample trial is shown in Fig. 1 . The final sample for the efficacy analysis included 534 perfor the efficacy analysis included 534 persons (154 women, median age 25.0 years; sons (154 women, median age 25.0 years; 380 men, median age 23.8 years), of whom 380 men, median age 23.8 years), of whom 349 had a DSM-IV diagnosis of schizo-349 had a DSM-IV diagnosis of schizophrenia, 149 schizophreniform disorder phrenia, 149 schizophreniform disorder and 36 schizoaffective disorder. Three perand 36 schizoaffective disorder. Three persons left the trial before treatment was sons left the trial before treatment was started but after randomisation, and one started but after randomisation, and one was removed from the trial for use of disalwas removed from the trial for use of disallowed medication before the trial. One lowed medication before the trial. One centre, which enrolled 21 patients, was centre, which enrolled 21 patients, was removed from the trial in the early stages removed from the trial in the early stages owing to violation of good clinical practice, owing to violation of good clinical practice, and data from those patients are not and data from those patients are not included in the analysis. Fourteen per cent included in the analysis. Fourteen per cent ( (n n¼76) of the sample had no high-school 76) of the sample had no high-school education, 26.6% ( education, 26.6% (n n¼141) had some 141) had some high-school education, 21.5% ( high-school education, 21.5% (n n¼114) 114) completed high school, 29.9% ( completed high school, 29.9% (n n¼159) 159) completed some post-high-school education completed some post-high-school education and 7.5% ( and 7.5% (n n¼40) completed college. 40) completed college. Women were significantly older at the time Women were significantly older at the time of first psychotic symptoms than men of first psychotic symptoms than men (median 23.9 years (median 23.9 years v v. 22.6 years; Mann-. 22.6 years; MannWhitney Whitney U U¼24154, 24154, z z¼2.89, 2.89, P P¼0.004). 0.004). Patients were treated and followed up until Patients were treated and followed up until the last patient to be enrolled had had the the last patient to be enrolled had had the opportunity to be treated for 1 year opportunity to be treated for 1 year (median duration of actual treatment 205 (median duration of actual treatment 205 days). days). , 1980 ) and a cognitive assessment battery. All measures were tive assessment battery. All measures were applied at baseline before drug administraapplied at baseline before drug administration and (with the exception of the PAS) at tion and (with the exception of the PAS) at regular intervals throughout the trial. regular intervals throughout the trial.
Assessments Assessments
The PAS is a 28-item rating scale of soThe PAS is a 28-item rating scale of social isolation, peer relationships, functioncial isolation, peer relationships, functioning outside of the family and school ing outside of the family and school performance for four age periods (ages up performance for four age periods (ages up to 11 years, 12-15 years, 16-18 years, to 11 years, 12-15 years, 16-18 years, and 19 years and above) as well as socialand 19 years and above) as well as socialsexual aspects of life starting at age 15 sexual aspects of life starting at age 15 years. The PAS also includes a section of years. The PAS also includes a section of nine general items relating to educational nine general items relating to educational and job achievement, work and school perand job achievement, work and school performance immediately preceding the onset formance immediately preceding the onset of psychosis, as well as the highest level of of psychosis, as well as the highest level of independence from family achieved, highest independence from family achieved, highest level of social personal adjustment, degree level of social personal adjustment, degree of interest in life and energy level. The of interest in life and energy level. The PAS was completed using all available data, PAS was completed using all available data, including interviewing the patient and including interviewing the patient and when available interviews with collateral when available interviews with collateral informants. A description of the PAS data informants. A description of the PAS data for this cohort has been presented elsefor this cohort has been presented elsewhere by Rabinowitz where by Rabinowitz et al et al (2002) . (2002). The cognitive assessment battery, The cognitive assessment battery, which is described in greater detail elsewhich is described in greater detail elsewhere (Harvey where (Harvey et al et al, 2003) , a test of psycho- , a test of psychomotor speed and attention; motor speed and attention; (f) (f) the Wisconsin Card Sorting Test the Wisconsin Card Sorting Test (Heaton (Heaton et al et al, 1993) , a measure of , 1993), a measure of executive functioning (e.g. cognitive executive functioning (e.g. cognitive flexibility, maintenance of a cognitive flexibility, maintenance of a cognitive set and working memory). set and working memory).
Cognitive testing was administered at Cognitive testing was administered at baseline, at months 3 and 6, and then every baseline, at months 3 and 6, and then every 6 months through to month 48. The tests, 6 months through to month 48. The tests, which were demonstrated to be comparable which were demonstrated to be comparable across cultures (Harvey across cultures (Harvey et al et al, 2003) , were , 2003), were translated from standard English versions translated from standard English versions into French, Finnish, German, Hebrew into French, Finnish, German, Hebrew and Afrikaans and administered to particiand Afrikaans and administered to participants in their native language. A central pants in their native language. A central monitoring facility evaluated case record monitoring facility evaluated case record forms, and all forms with errors were reforms, and all forms with errors were returned for correction. If the problems were turned for correction. If the problems were the results of errors in administration, the the results of errors in administration, the cognitive testing data on those patients cognitive testing data on those patients were not included in the study database were not included in the study database (Harvey (Harvey et al et al, 2005) . All testers and asses-, 2005). All testers and assessors were college-educated, had previous sors were college-educated, had previous experience and were fluent in English, experience and were fluent in English, although testing was done in the local although testing was done in the local language. Training in administering all the language. Training in administering all the study assessment instruments was given in study assessment instruments was given in small group training sessions at the local small group training sessions at the local sites, as well as in regional meetings. sites, as well as in regional meetings.
The PAS was completed for 530 of the The PAS was completed for 530 of the 534 participants, the PANSS for 533 and 534 participants, the PANSS for 533 and the cognitive assessment for 508, with the cognitive assessment for 508, with completed data on all measures available completed data on all measures available for 503 participants. On the PAS, our main for 503 participants. On the PAS, our main study measure, data per item were missing study measure, data per item were missing as follows: on the childhood items only 1 as follows: on the childhood items only 1 case had missing data on one item; on the case had missing data on one item; on the early adolescence items data were missing early adolescence items data were missing in 2-6 cases for any given item; on late in 2-6 cases for any given item; on late adolescence 2-12 cases had missing data adolescence 2-12 cases had missing data for any given item, with the most missing for any given item, with the most missing data on social aspects of sexual life during data on social aspects of sexual life during adolescence and immediately beyond; for adolescence and immediately beyond; for adulthood items, which were to be comadulthood items, which were to be completed only for persons aged 19 years and pleted only for persons aged 19 years and over, data were missing in 9 cases for two over, data were missing in 9 cases for two items. On four of the six general items the items. On four of the six general items the maximum number of missing cases per item maximum number of missing cases per item was 2; on one item (change in school or was 2; on one item (change in school or work performance before onset) data were work performance before onset) data were missing in 20 cases and on a similar item missing in 20 cases and on a similar item (measuring job change and school (measuring job change and school attendance) data were missing in 18 cases. attendance) data were missing in 18 cases.
Statistical analysis Statistical analysis
Using the scoring method developed by Using the scoring method developed by Cannon-Spoor Cannon- Spoor et al et al (1982) for the PAS, (1982) for the PAS, average scores for each life stage were average scores for each life stage were computed by summing the item scores recomputed by summing the item scores received for each item in a section and dividceived for each item in a section and dividing them by the possible score. The possible ing them by the possible score. The possible score is the highest score obtainable by score is the highest score obtainable by adding the maximum score for all items adding the maximum score for all items completed. Thus, for example, if a person completed. Thus, for example, if a person receives ratings of 2, 3, 3 and 2 for the four receives ratings of 2, 3, 3 and 2 for the four items in the childhood section, the total items in the childhood section, the total score for that section would be 10. As the score for that section would be 10. As the total possible score for this is 24 total possible score for this is 24 (6+6+6+6), the total score divided by the (6+6+6+6), the total score divided by the possible score in this example is 0.42. possible score in this example is 0.42. When no information was available for a When no information was available for a particular item, the item was not scored. particular item, the item was not scored. The score for the section is expressed as The score for the section is expressed as total score/possible score for the items total score/possible score for the items rated. rated.
For typology of premorbid functioning, For typology of premorbid functioning, as in other studies (Larsen as in other studies (Larsen et al et al, 1996; Ra-, 1996 Flow of participants through study. 'a pattern of worsening scores from childhood 'a pattern of worsening scores from childhood over the remaining premorbid periods and the over the remaining premorbid periods and the equivalent of a two-point change over four preequivalent of a two-point change over four premorbid stages (childhood, early adolescence, morbid stages (childhood, early adolescence, late adolescence and adulthood) or a proporlate adolescence and adulthood) or a proportional decline for cases in which illness onset was tional decline for cases in which illness onset was before late adolescence or adulthood' (Haas & before late adolescence or adulthood' (Haas & Sweeney,1992) . Sweeney,1992) .
In accordance with the scoring criteria, In accordance with the scoring criteria, the remaining cases were regarded as stable the remaining cases were regarded as stable and the median value (0.36) of the PAS and the median value (0.36) of the PAS total score was used as a cut-off point to total score was used as a cut-off point to divide the cases into 'stable-good' and divide the cases into 'stable-good' and 'stable-poor' groups. Based on this, 47% 'stable-poor' groups. Based on this, 47% ( (n n¼251) of the patients were in the 251) of the patients were in the 'stable-good' group, 37% ( 'stable-good' group, 37% (n n¼198) in the 198) in the 'stable-poor' group and 15% ( 'stable-poor' group and 15% (n n¼81) in 81) in the 'declining' group. This distribution rethe 'declining' group. This distribution resembles other studies using this classificasembles other studies using this classification method, in which the 'stable-good' tion method, in which the 'stable-good' group ranged from 30% to 39%, the group ranged from 30% to 39%, the 'stable-poor' group from 28% to 39% 'stable-poor' group from 28% to 39% and the 'declining' group from 21% to and the 'declining' group from 21% to 42% (Haas & Sweeney, 1992; Larsen 42% (Haas & Sweeney, 1992; Larsen et et al al, 1996; Strous , 1996; Strous et al et al, 2004) . , 2004). Univariate analyses of covariance comUnivariate analyses of covariance comparing the premorbid groups on change paring the premorbid groups on change from baseline on PANSS total, ESRS maxifrom baseline on PANSS total, ESRS maximum, CGI Severity, CGI Change score, mum, CGI Severity, CGI Change score, mean modal dose and composite cognitive mean modal dose and composite cognitive score, were conducted while controlling score, were conducted while controlling for baseline score for each measure, for baseline score for each measure, diagnosis, gender, age, study centre and diagnosis, gender, age, study centre and randomised drug treatment condition. For randomised drug treatment condition. For CGI Change scores the CGI severity was CGI Change scores the CGI severity was used as a baseline control. The composite used as a baseline control. The composite cognitive score was created by computing cognitive score was created by computing the mean of the the mean of the z z-scores for each cognitive -scores for each cognitive measure in the current study, as described measure in the current study, as described by Harvey by Harvey et al et al (2005) . Follow-up tests (2005) . Follow-up tests using the least-squares procedure were used using the least-squares procedure were used after detection of significant between-group after detection of significant between-group differences. Effect size for the primary comdifferences. Effect size for the primary comparison of the 'stable-good' and 'stableparison of the 'stable-good' and 'stablepoor' groups was calculated using eta poor' groups was calculated using eta squared and for ease of reporting was consquared and for ease of reporting was converted to Cohen's verted to Cohen's d d , which , which is the difference between groups divided is the difference between groups divided by the pooled standard deviation. Cohen by the pooled standard deviation. has defined effect sizes of 0.20-(1976) has defined effect sizes of 0.20-0.50 as small, 0.50-0.80 as medium and 0.50 as small, 0.50-0.80 as medium and over 0.80 as large. over 0.80 as large. Table 1 shows significantly more improve- Table 1 shows significantly more improvement in the 'stable-good' group compared ment in the 'stable-good' group compared with the 'stable-poor' group on the mean with the 'stable-poor' group on the mean change in PANSS total, positive, negative change in PANSS total, positive, negative and general psychopathology scales, CGI and general psychopathology scales, CGI Severity, cognitive functioning and CGI Severity, cognitive functioning and CGI Improvement. The 'stable-good' group also Improvement. The 'stable-good' group also had lower dosages. Although numerically had lower dosages. Although numerically the 'stable-good' group had lower the 'stable-good' group had lower maximum ESRS scores than the 'stablemaximum ESRS scores than the 'stablepoor' group poor' group, these differences were not , these differences were not statistically significant. All effect size statistically significant. All effect size scores were small, ranging from 0.11 to scores were small, ranging from 0.11 to 0.35. 0.35.
RESULTS RESULTS
The 'declining' group comparisons with The 'declining' group comparisons with the 'stable-good' group were similar to the 'stable-good' group were similar to those of the 'stable-poor' group. Numerithose of the 'stable-poor' group. Numerically those in the 'declining' group cally those in the 'declining' group improved the least, had the most extrapyrimproved the least, had the most extrapyramidal signs and were treated with the amidal signs and were treated with the highest drug dosages. After including mode highest drug dosages. After including mode antipsychotic dosage as a covariate in the antipsychotic dosage as a covariate in the model, testing differences on the ESRS, model, testing differences on the ESRS, the ESRS differences were reduced the ESRS differences were reduced ( (F F¼1.45, 1.45, P P¼0.23, effect size 0.23, effect size¼0.11 0.11 v v. . F F¼0.50, effect size 0.50, effect size¼0.06, 0.06, P P¼0.44), sug-0.44), suggesting that most of the association begesting that most of the association between better premorbid adjustment and tween better premorbid adjustment and fewer extrapyramidal symptoms was owing fewer extrapyramidal symptoms was owing to drug doses. to drug doses.
DISCUSSION DISCUSSION
The results of this study demonstrate that The results of this study demonstrate that good good v v. poor and declining premorbid . poor and declining premorbid functioning of people who later develop functioning of people who later develop schizophrenia was associated with better schizophrenia was associated with better treatment response. The good premorbid treatment response. The good premorbid functioning group also needed lower doses functioning group also needed lower doses of antipsychotic medication to achieve of antipsychotic medication to achieve clinically satisfactory treatment response clinically satisfactory treatment response and experienced the least extrapyramidal and experienced the least extrapyramidal symptoms. The results thus support the symptoms. The results thus support the prognostic value of premorbid functioning prognostic value of premorbid functioning in predicting magnitude of response when in predicting magnitude of response when treatment is first started and suggest that treatment is first started and suggest that premorbid functioning might be a potenpremorbid functioning might be a potentially useful subtyping distinction of tially useful subtyping distinction of patients. Clinically, it might be possible to patients. Clinically, it might be possible to use premorbid subtyping in treatment use premorbid subtyping in treatment planning: prognosis regarding treatment planning: prognosis regarding treatment response could be modified based on response could be modified based on premorbid course and patients with other premorbid course and patients with other than 'stable-good' premorbid functioning than 'stable-good' premorbid functioning could be targeted for more intensive theracould be targeted for more intensive therapeutic intervention. Specifically, such cases peutic intervention. Specifically, such cases should probably receive more rapid conshould probably receive more rapid consideration for transition to clozapine treatsideration for transition to clozapine treatment or treatment with more aggressive ment or treatment with more aggressive dosing regimens. The results also suggest that from the perspecresults also suggest that from the perspective of treatment response there is no tive of treatment response there is no difference between the 'stable-poor' and difference between the 'stable-poor' and 'declining' groups, both of whom showed 'declining' groups, both of whom showed poor treatment response. Thus, lack of poor treatment response. Thus, lack of decline in functioning from previously poor decline in functioning from previously poor levels of functioning appears not to be an levels of functioning appears not to be an indicator of better prognosis. indicator of better prognosis.
One of the limitations of this study, and One of the limitations of this study, and other studies, is that the quality and timing other studies, is that the quality and timing of premorbid manifestations that are based of premorbid manifestations that are based on cross-sectional assessments conducted on cross-sectional assessments conducted generally at the first contact with a mental generally at the first contact with a mental health professional (McGlashan, 1988) health professional (McGlashan, 1988) could be biased by selective or incomplete could be biased by selective or incomplete recall on the part of the patients or family recall on the part of the patients or family members. In addition the assessments were members. In addition the assessments were not always based on the same sources of not always based on the same sources of information, which were in some cases information, which were in some cases interviews with patients and in others interinterviews with patients and in others interviews with collateral informants as well. It views with collateral informants as well. It is conceivable that a truly prospective is conceivable that a truly prospective follow-up study, specifically designed to follow-up study, specifically designed to detect signs of premorbid psychosis and detect signs of premorbid psychosis and schizophrenia and conducted from birth schizophrenia and conducted from birth through age of risk, would reveal a specific through age of risk, would reveal a specific trajectory of social maladjustment for the trajectory of social maladjustment for the majority of the individuals destined to be majority of the individuals destined to be affected by psychosis. Alternatively, it is affected by psychosis. Alternatively, it is possible that the premorbid and prodromal possible that the premorbid and prodromal manifestations are obligatory precursors of manifestations are obligatory precursors of the illness only for some of the individuals the illness only for some of the individuals affected or only for a subgroup of the schiaffected or only for a subgroup of the schizophrenias. Another potential limitation of zophrenias. Another potential limitation of the study is that since data were obtained the study is that since data were obtained from a sample of patients who agreed to from a sample of patients who agreed to be enrolled in a medication trial, this might be enrolled in a medication trial, this might have introduced a selection bias; however, have introduced a selection bias; however, it is not obvious how this might limit the it is not obvious how this might limit the conclusions that can be drawn from the conclusions that can be drawn from the study. Another limitation is that only study. Another limitation is that only clinical outcomes, rather than functional clinical outcomes, rather than functional outcomes such as social and occupational outcomes such as social and occupational functioning, were examined. functioning, were examined.
In summary, our results, taken together In summary, our results, taken together with previous studies including the baseline with previous studies including the baseline data from this large cohort (Rabinowitz data from this large cohort (Rabinowitz et et al al, 2002) , suggest that premorbid level of , 2002), suggest that premorbid level of functioning is predictive of poorer funcfunctioning is predictive of poorer functioning at the time of onset of schizotioning at the time of onset of schizophrenia (Haas & Sweeney, 1992; Kelley phrenia (Haas & Sweeney, 1992; Kelley et al et al, 1992; Larsen , 1992; Larsen et al et al, 1996; Rabinowitz , 1996; Rabinowitz et al et al, 2002) , poorer outcomes and func-, 2002), poorer outcomes and functioning among patients with first-episode tioning among patients with first-episode (Shtasel (Shtasel et al et al, 1992; Bromet , 1992; Bromet et al et al, 1996; , 1996; Silverstein Silverstein et al et al, 2002 , 2003 or chronic dis-, 2002, 2003) or chronic disorder (Gittelman-Klein & Klein, 1969; order (Gittelman-Klein & Klein, 1969; Cannon-Spoor Cannon-Spoor et al et al, 1982; Keefe , 1982; Keefe et al et al, , 1989; Childers & Harding, 1990; Findling 1989; Childers & Harding, 1990; Findling et al et al, 1996; Rabinowitz , 1996; Rabinowitz et al et al, 2005 Rabinowitz et al et al, ) and, , 2005 and, based on the current study, also poorer based on the current study, also poorer treatment response. Premorbid functioning treatment response. Premorbid functioning is thus of both clinical and theoretical is thus of both clinical and theoretical importance and may suggest the need to importance and may suggest the need to consider aggressive intervention, either consider aggressive intervention, either pharmacological or psychosocial, at the pharmacological or psychosocial, at the time of the first episode of illness. time of the first episode of illness.
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